Our vision

Oxcia AB vision is to transform state-of-art science into valuable drugs and health products to improve lives.

Organisation


Chairman of the Board
ulrika.warpmanberglund@oxcia.se


CEO, Member of the Board
jan.zetterberg@oxcia.se
 

General Counsel and Member of the Board
johannes.linde@oxcia.se
 

Member of the Board
annika.jenmalmjensen@oxcia.se
 

Head of administration and accounting
hakan.nordlander@oxcia.se

Head of Clinical Development
teresa.sandvall@oxcia.se
 

Head of Intellectual property
kerstin.genetay@oxcia.se 

CMC Director
martin.scobie@oxcia.se
 
 

Get to know us


Chairman of the Board
ulrika.warpmanberglund@oxcia.se

Ulrika Warpman Berglund is a Pharmacist and has a PhD in Pharmacology. She joined Pharmacia in 1997, where she worked as a scientist, section head and project leader. In 2000 she joined Biovitrum as project leader as well as group leader.

In 2009, Ulrika left Sweden to join Prosidion Ltd in Oxford, UK, where she successfully established a pharmacology department and was part of the Research steering group. Ulrika has proven strong leader qualities and drug discovery know how in a number of multi-disciplinary project teams, pharmacology teams, steering teams and during restructuring processes and thereby gained confidence in her ability of strategic thinking, as well as her ability to set up visions, organise and establish new teams, communicate, and collaborate. She has directed business goals and together with her teams significantly contributed towards achieving them. Ulrika has successfully managed research projects leading to outlicensing of projects and developing of clinical candidates. In 2012, she joined Professor Helleday at Karolinska Institute to perform drug discovery in an academic setting.


CEO, Member of the Board
jan.zetterberg@oxcia.se

Jan Zetterberg finished law studies in 1975 after which he worked for the Swedish Court system until 1979. He joined AstraZeneca (Astra) in 1983 where he held several roles such as Legal Counsel, Senior Counsel, Vice President, Strategy, Intellectual Property and since 1999 as Assistant General Counsel.

Jan Zetterberg provided global legal support in all areas of business including corporate functions, R&D, Operations, and Business Development. In addition he was appointed line manager for AstraZeneca Trademarks group in 2008. Jan Zetterberg retired from AstraZeneca end 2011. He started Zedur AB in January 2012 to provide consultancy services in the legal and compliance area supporting primarily small to medium size Life Science industry. He became Partner and Chairman of the Board of Zelibra AB in January 2012. Zelibra AB is a Swedish company offering the services of internationally experienced consultants to the life science industry. Its mission is to help bring life science innovations to the right market in a timely and cost-effective manner. In January 2014 Jan Zetterberg was elected Chairman of the Board of ExThera AB.


General Counsel and Member of the Board
johannes.linde@oxcia.se

Johannes Linde is co-founder and the Chairman of Sapphire Solutions AB. He is a client focused legal advisor with more than 25 years of experience in providing a broad range of legal and business advice from various global positions within AstraZeneca’s Legal department and R&D function.

He has served as secretary of the board of AstraZeneca AB (1999 – 2006 and 2012 – 2013) and has designed and led international legal teams with members located across the world. He has been a member of the global leadership teams of both the Legal Department and the R&D function of AstraZeneca. Johannes is an effective team leader with strong leadership capabilities and with outstanding communication skills. He has a proven track record in negotiating and driving numerous complex strategic business transactions.


Member of the Board
annika.jenmalmjensen@oxcia.se

Annika Jenmalm Jensen is a pharmacist by training and finished her PhD in Medicinal Chemistry in 1998 at Uppsala University. She joined Pharmacia immediately after as a medicinal chemist.

In 2000 she joined Biovitrum as a chemistry team leader and later as project leader. In 2009, Annika left Biovitrum and started to work towards the inauguration of Chemical Biology Consortium Sweden (CBCS) which is a not-for-profit national infrastructure of Chemical Biology. Between 2010-2016 she held the position as the Director of CBCS and as well as a group leader of Laboratories of Chemical Biology Karolinska institutet (LCBKI). In 2016 she was appointed Infrastructure Director at SciLifeLab which she combines with a position as researcher at CBCS and head of division at MBB, KI. Annika has a passion for Drug Discovery and believes highly in performing the early preclinical research in close collaboration with the academic setting. Her leadership is visionary and she has excellent communication skills.


Head of administration and accounting
hakan.nordlander@oxcia.se

Håkan Nordlander have 38 years of work experience, including work in Audit Company and a position as CFO but mainly 30 years of employment in AstraZeneca in different positions in the financial area.

My main expertise is in the areas of accounting, budgeting and financial reporting but I have also experience from Mergers & acquisitions and I have also over a long period of time been responsible for a number of global deals from a finance perspective. The global deals has been In and out licensing deals as well as Co- promotion and Global Alliances deals.


Head of Clinical Development
teresa.sandvall@oxcia.se

Teresa Sandvall a clinical trials specialist with 16 years of experience from the pharmaceutical industry (i.e. Biovitrum and Novartis) as well as working at Karolinska University Hospital as a start up- specialist regarding clinical trials and with the Swedish CardioPulmonary bioImage Study (SCAPIS).

That is a world unique project in the field of heart, blood vessels and lungs in collaboration with academia and the Swedish Heart and Lung Foundation. She has experience from all aspects of clinical trials from small studies to large multi-centre studies, from Phase 1 to phase 3, and provides knowledge on regulatory requirements and strategies, guidelines, protocol assistance, planning, initiating, executing and finalizing clinical trials. Teresa has also been working as a research scientist in preclinical projects with drug design to find new drug candidates and involved in driving projects from early to late preclinical phase.


Head of Intellectual property
kerstin.genetay@oxcia.se

Kerstin Genetay has worked more than 20 years as coordinator of development & IP projects in the pharmaceutical industry, both in Big Pharma (Pharmacia & Pfizer) and smaller Biotech.

She has major experience of Project Portfolio Management with particular emphasis on prioritization of projects and subsequent patent portfolio management. Kerstin is a Swedish representative in ISO, relating to Medical Devices Technology and has managed projects of device – pharmaceutical compatibility & medical device related intellectual property issues. Kerstin has Dr Med Sc in molecular genetics & bacteriology from the Karolinska Institute.


CMC Director
martin.scobie@oxcia.se

Martin Scobie received a PhD in chemistry from the University of Edinburgh. After post-doctoral studies at the Universities of Geneva, Bath and Strathclyde, he was one of the first scientists recruited by the start-up company Oxford Diversity PLC where he worked as project leader from 1995-2000, gaining commercial and project management experience on a number of successful programs.

In 2000 he moved to Uppsala in Sweden where he worked first with Pharmacia AB, then Biovitrum AB in medicinal chemistry team leader roles. In 2010 he was recruited by Prof. Thomas Helleday to build-up a medicinal chemistry team in the Helleday Lab. The team is based at Karolinska Institutet and is focused on developing inhibitors to novel targets involved in DNA repair and metabolism. Since 2013 Martin has been closely involved in CMC and pharmaceutical development of Karonudib (Oxcia’s MTH1 inhibitor which is currently in clinical trials), and in the discovery of several other small molecule inhibitors in Oxcia’s pipeline.